Wave’s new capital extends cash runway into 2027, CEO says

Max Bayer

Pharma Reporter

Wave Life Sciences brought in $230 million through an upsized public offering, extending its cash runway into 2027 as a handful of key programs advance …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Wave’s new capital extends cash runway into 2027, CEO says

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Lilly invests $4.5B in new Indiana site to bring clinical manufacturing in-house

Exclusive: After discovering antibiotics with AI, a 31-year-old first-time CEO raises $17M to fight aging

Scoop: Founding CEO leaves Atomwise, casting doubt over a once high-flying AI startup

Frazier adds $630M to public fund to 'take advantage of market volatility'

UK biotech bags $43M in Series A to move Huntington's drug into first human study

3 Tiers for AAV Potency Assay Development Success

Wave’s new cap­i­tal ex­tends cash run­way in­to 2027, CEO says

Pharma Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Wave’s new capital extends cash runway into 2027, CEO says